PT1976548E - Fragmentos de vip e suas composições - Google Patents

Fragmentos de vip e suas composições Download PDF

Info

Publication number
PT1976548E
PT1976548E PT68176031T PT06817603T PT1976548E PT 1976548 E PT1976548 E PT 1976548E PT 68176031 T PT68176031 T PT 68176031T PT 06817603 T PT06817603 T PT 06817603T PT 1976548 E PT1976548 E PT 1976548E
Authority
PT
Portugal
Prior art keywords
compositions
vip fragments
vip
fragments
Prior art date
Application number
PT68176031T
Other languages
English (en)
Inventor
Karen Annette Duggan
Original Assignee
Vectus Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38122420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1976548(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2005906947A external-priority patent/AU2005906947A0/en
Application filed by Vectus Biosystems Ltd filed Critical Vectus Biosystems Ltd
Publication of PT1976548E publication Critical patent/PT1976548E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PT68176031T 2005-12-09 2006-12-08 Fragmentos de vip e suas composições PT1976548E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2005906947A AU2005906947A0 (en) 2005-12-09 VIP fragments and methods of use

Publications (1)

Publication Number Publication Date
PT1976548E true PT1976548E (pt) 2014-10-13

Family

ID=38122420

Family Applications (1)

Application Number Title Priority Date Filing Date
PT68176031T PT1976548E (pt) 2005-12-09 2006-12-08 Fragmentos de vip e suas composições

Country Status (20)

Country Link
US (4) US8470778B2 (pt)
EP (2) EP2783697B1 (pt)
JP (3) JP5449778B2 (pt)
KR (2) KR101404561B1 (pt)
CN (2) CN101325964B (pt)
AR (2) AR058308A1 (pt)
AU (1) AU2006322656B2 (pt)
BR (1) BRPI0620566B8 (pt)
CA (2) CA2632581C (pt)
DK (2) DK2783697T3 (pt)
ES (2) ES2621864T3 (pt)
HK (1) HK1122746A1 (pt)
IL (3) IL192046A (pt)
NZ (4) NZ623674A (pt)
PL (1) PL1976548T3 (pt)
PT (1) PT1976548E (pt)
RU (1) RU2466738C2 (pt)
TW (1) TWI402273B (pt)
WO (1) WO2007065226A1 (pt)
ZA (1) ZA200805837B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120545A1 (en) * 2004-06-11 2005-12-22 Vectus Biosystems Limited Compositions and methods for treatment of cardiovascular disease
EP1912724A2 (en) * 2005-07-28 2008-04-23 Global Research Technologies, LLC Removal of carbon dioxide from air
DK2783697T3 (en) 2005-12-09 2017-04-10 Vectus Biosystems Ltd VIP Fragments and uses thereof
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP1971355B1 (en) 2005-12-20 2020-03-11 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
WO2009158704A2 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
KR101671406B1 (ko) 2008-10-17 2016-11-01 벡투스 바이오시스템즈 리미티드 신장 장애 치료용 조성물 및 방법
CN101434649B (zh) * 2008-12-12 2012-04-25 余榕捷 一种环七肽及其制备方法和应用
US8729020B2 (en) * 2009-04-02 2014-05-20 Vectus Biosystems Pty Ltd Methods for the treatment of aortic fibrosis with VIP fragments
AU2010282250B2 (en) * 2009-08-14 2015-11-12 Immunoforge Co., Ltd. Modified Vasoactive Intestinal Peptides
CA2873553C (en) 2011-06-06 2020-01-28 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
BR112016005601B1 (pt) * 2013-09-17 2021-02-02 Vectus Biosystems Limited composto, composição farmacêutica, e usos de um composto
US9375638B2 (en) * 2014-01-02 2016-06-28 Lloyd A. Weaver Game console switch box
US11052132B2 (en) 2014-05-08 2021-07-06 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
EP3256151B1 (en) * 2015-02-09 2020-08-05 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862927A (en) * 1973-02-26 1975-01-28 Sami I Said Process for preparation of vasoactive intestinal peptide
US4016258A (en) * 1975-08-05 1977-04-05 Said Sami I Vasoactive intestinal peptide from fowl
US4237046A (en) * 1979-04-27 1980-12-02 Miklos Bodanszky Polypeptides and methods of preparation
GB8427651D0 (en) * 1984-11-01 1984-12-05 Beecham Group Plc Compounds
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
US5972883A (en) * 1993-03-16 1999-10-26 Yeda Research And Development Co. Ltd. Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
US5808037A (en) * 1995-09-15 1998-09-15 Ramareddy Venkata Guntaka Oligomers which inhibit expression of collagen genes
US20020115609A1 (en) * 1997-07-14 2002-08-22 Hayat Onyuksel Materials and methods for making improved micelle compositions
US5892162A (en) * 1997-11-18 1999-04-06 Southwest Research Institute Apparatus and method for inspection of pipes and tubes using guided wave probe
WO2001035961A1 (en) * 1999-10-29 2001-05-25 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
WO2002034285A2 (en) * 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
JP2004514697A (ja) * 2000-11-28 2004-05-20 モンドバイオテック・ソシエテ・アノニム 肺及び細動脈高血圧症治療用の血管作動性腸管ペプチドの生物学的活性をもつ化合物
US6911430B2 (en) * 2003-10-01 2005-06-28 Vipogen, Llc Compositions and methods for treating ileus
CA2566310C (en) * 2004-05-21 2014-05-13 Lawrence Solomon Scored pharmaceutical tablets comprising a plurality of segments
CA2567635A1 (en) * 2004-05-21 2005-12-01 Eli Lilly And Company Selective vpac2 receptor peptide agonists
WO2005120545A1 (en) * 2004-06-11 2005-12-22 Vectus Biosystems Limited Compositions and methods for treatment of cardiovascular disease
DK2783697T3 (en) * 2005-12-09 2017-04-10 Vectus Biosystems Ltd VIP Fragments and uses thereof
US20100044560A1 (en) * 2006-07-06 2010-02-25 Franco Basile Method and Apparatus for Pyrolysis-Induced Cleavage in Peptides and Proteins
KR101671406B1 (ko) * 2008-10-17 2016-11-01 벡투스 바이오시스템즈 리미티드 신장 장애 치료용 조성물 및 방법
US8729020B2 (en) * 2009-04-02 2014-05-20 Vectus Biosystems Pty Ltd Methods for the treatment of aortic fibrosis with VIP fragments

Also Published As

Publication number Publication date
JP2012229222A (ja) 2012-11-22
KR20080075551A (ko) 2008-08-18
BRPI0620566B1 (pt) 2018-07-24
JP2009518316A (ja) 2009-05-07
JP2014097994A (ja) 2014-05-29
CN103450345A (zh) 2013-12-18
US20130244934A1 (en) 2013-09-19
CA2632581A1 (en) 2007-06-14
JP5847793B2 (ja) 2016-01-27
KR101404561B1 (ko) 2014-06-11
HK1122746A1 (en) 2009-05-29
EP2783697A2 (en) 2014-10-01
US20090005315A1 (en) 2009-01-01
RU2008127877A (ru) 2010-01-20
NZ597677A (en) 2013-05-31
EP1976548A4 (en) 2012-04-18
JP5730820B2 (ja) 2015-06-10
EP2783697B1 (en) 2017-01-11
US8916523B2 (en) 2014-12-23
ES2523858T3 (es) 2014-12-02
IL192046A0 (en) 2008-12-29
JP5449778B2 (ja) 2014-03-19
AR109274A2 (es) 2018-11-14
DK2783697T3 (en) 2017-04-10
US20150065424A1 (en) 2015-03-05
IL224609A (en) 2014-05-28
KR20140041943A (ko) 2014-04-04
BRPI0620566A2 (pt) 2011-11-16
BRPI0620566B8 (pt) 2021-05-25
PL1976548T3 (pl) 2015-01-30
CA2952475A1 (en) 2007-06-14
EP1976548A1 (en) 2008-10-08
IL192046A (en) 2014-03-31
CN101325964B (zh) 2013-09-18
AR058308A1 (es) 2008-01-30
TW200730538A (en) 2007-08-16
NZ623674A (en) 2014-07-25
CN101325964A (zh) 2008-12-17
RU2466738C2 (ru) 2012-11-20
CA2952475C (en) 2022-08-09
IL230534A (en) 2014-12-31
EP1976548B1 (en) 2014-07-02
AU2006322656B2 (en) 2012-03-08
EP2783697A3 (en) 2015-01-07
DK1976548T3 (da) 2014-10-06
US20160222078A1 (en) 2016-08-04
WO2007065226A1 (en) 2007-06-14
ES2621864T3 (es) 2017-07-05
US9340583B2 (en) 2016-05-17
NZ569401A (en) 2012-03-30
AU2006322656A1 (en) 2007-06-14
NZ604248A (en) 2014-07-25
US8470778B2 (en) 2013-06-25
CN103450345B (zh) 2016-04-20
ZA200805837B (en) 2009-05-27
CA2632581C (en) 2017-02-07
TWI402273B (zh) 2013-07-21
US9732136B2 (en) 2017-08-15

Similar Documents

Publication Publication Date Title
HK1122746A1 (en) Vip fragments and compositions thereof
EP1895838A4 (en) COMPOSITIONS AND METHODS
PL1883665T3 (pl) Kompozycje polilaktydowe i ich zastosowania
GB0522287D0 (en) Method and compositions
PL1951838T3 (pl) Kompozycje zawierające fluoroolefiny i ich zastosowania
EP1879659A4 (en) REIZARING COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
HK1128487A1 (en) Compositions comprising fluoroolefins and uses thereof
GB0525314D0 (en) Method and composition
IL187617A0 (en) Lkktet and/or lkktnt peptide compositions and methods
ZA200704295B (en) Arthrospira-based compositions and uses thereof
IL184834A0 (en) Compositions and methods for the manufacture thereof
EP1848438A4 (en) DIAMINOPHENOTHIAZINE COMPOSITIONS AND THEIR USE
GB0617171D0 (en) Novel compositions and methods
GB0524927D0 (en) Compositions and method
ZA200805079B (en) Immunostimulatory compositions and methods
ZA200802969B (en) Composition and method
GB0522655D0 (en) Composition and method
GB0501348D0 (en) Compositions and methods
GB0511235D0 (en) Compositions and method
ZA200604686B (en) Mortar compositions, methods and applications therefor
EP1924257A4 (en) STABILIZED 3-HYDROXYFLAVAN COMPOSITIONS AND METHOD THEREFOR
GB0504185D0 (en) Improved glazing composition and uses thereof
GB0525968D0 (en) Compositions and methods
GB0502889D0 (en) Novel method and compositions
GB0505012D0 (en) Composition and method